Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810394 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00810394 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 50 participants.
The verdict
NCT00810394, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and best dose of sorafenib and to see how well it works in treating patients with advanced malignant solid tumors.
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00810394
The ClinicalTrials.gov registry entry for NCT00810394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT00810394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00810394 about?
NCT00810394 is a clinical study titled "Sorafenib in Treating Patients With Advanced Malignant Solid Tumors". RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and best dose of sorafenib and to see how well it works in treating patients with advance...
What is the current status of trial NCT00810394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-12. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00810394?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00810394?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.